Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Masked, Vehicle-Controlled Parallel Group Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease

NCT06389214 is registered in ClinicalTrials.gov with Aldeyra Therapeutics, Inc. as lead sponsor.

NCT NCT06389214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06389214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Masked, Vehicle-Controlled Parallel Group Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease
Lead sponsor
Aldeyra Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 9, 2024
Completion date
June 11, 2024
Enrollment
132 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye disease